# Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

> **NCT00062660** · — · APPROVED_FOR_MARKETING · sponsor: **Boehringer Ingelheim**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tipranavir

## Key facts

- **NCT ID:** NCT00062660
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** 2003-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** — (—)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062660, "Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00062660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*